1887

Abstract

As a superantigen, staphylococcal enterotoxin C2 (SEC2) has commonly been used as an antitumour immunotherapy agent in China. However, the clinical application of SEC2 has been hampered by its pyrogenic toxicity and the presence of neutralizing antibody in patients. Thus, an improvement in its superantigen-based immunotherapy is highly needed. In this study, a truncated SEC2 mutant, SEC(14–128), was constructed without the N-terminal 13 and C-terminal 111 aa. This mutant retained T-cell proliferation and antitumour activities in experiments. However, it induced a significantly decreased release of the main inflammatory cytokines inerleukin-2 and gamma interferon. Moreover, SEC(14–128) exhibited reduced toxicity and affinity to anti-SEC2 IgG compared with native SEC2. Based on the considerable antitumour activity and low toxicity, it is proposed that the mutant SEC(14–128) could be a potential candidate for cancer treatment.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.047472-0
2013-03-01
2019-12-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/3/451.html?itemId=/content/journal/jmm/10.1099/jmm.0.047472-0&mimeType=html&fmt=ahah

References

  1. Chen T. Z.. ( 2005;). The basis and criteria for the effective dose of SEC2 oral liquid. . Prog Microbiol Immunol 33:, 51–58.
    [Google Scholar]
  2. Dinges M. M., Orwin P. M., Schlievert P. M.. ( 2000;). Exotoxins of Staphylococcus aureus. . Clin Microbiol Rev 13:, 16–34. [CrossRef][PubMed]
    [Google Scholar]
  3. Dohlsten M., Abrahmsén L., Björk P., Lando P. A., Hedlund G., Forsberg G., Brodin T., Gascoigne N. R., Förberg C., Lind P.. ( 1994;). Monoclonal antibody–superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. . Proc Natl Acad Sci U S A 91:, 8945–8949. [CrossRef][PubMed]
    [Google Scholar]
  4. Hoffmann M. L., Jablonski L. M., Crum K. K., Hackett S. P., Chi Y.-I., Stauffacher C. V., Stevens D. L., Bohach G. A.. ( 1994;). Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylococcal enterotoxin C1. . Infect Immun 62:, 3396–3407.[PubMed]
    [Google Scholar]
  5. Hovde C. J., Hackett S. P., Bohach G. A.. ( 1990;). Nucleotide sequence of the staphylococcal enterotoxin C3 gene: sequence comparison of all three type C staphylococcal enterotoxins. . Mol Gen Genet 220:, 329–333. [CrossRef][PubMed]
    [Google Scholar]
  6. Letertre C., Perelle S., Dilasser F., Fach P.. ( 2003;). Identification of a new putative enterotoxin SEU encoded by the egc cluster of Staphylococcus aureus. . J Appl Microbiol 95:, 38–43. [CrossRef][PubMed]
    [Google Scholar]
  7. Llewelyn M., Cohen J.. ( 2002;). Superantigens: microbial agents that corrupt immunity. . Lancet Infect Dis 2:, 156–162. [CrossRef][PubMed]
    [Google Scholar]
  8. Mondal T. K., Bhatta D., Biswas S., Pal P.. ( 2002;). Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide. . Biochem Biophys Res Commun 290:, 1336–1342. [CrossRef][PubMed]
    [Google Scholar]
  9. Mosmann T.. ( 1983;). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. . J Immunol Methods 65:, 55–63. [CrossRef][PubMed]
    [Google Scholar]
  10. Müller-Alouf H., Carnoy C., Simonet M., Alouf J. E.. ( 2001;). Superantigen bacterial toxins: state of the art. . Toxicon 39:, 1691–1701. [CrossRef][PubMed]
    [Google Scholar]
  11. Munson S. H., Tremaine M. T., Betley M. J., Welch R. A.. ( 1998;). Identification and characterization of staphylococcal enterotoxin types G and I from Staphylococcus aureus. . Infect Immun 66:, 3337–3348.[PubMed]
    [Google Scholar]
  12. Ono H. K., Omoe K., Imanishi K., Iwakabe Y., Hu D.-L., Kato H., Saito N., Nakane A., Uchiyama T., Shinagawa K.. ( 2008;). Identification and characterization of two novel staphylococcal enterotoxins, types S and T. . Infect Immun 76:, 4999–5005. [CrossRef][PubMed]
    [Google Scholar]
  13. Papageorgiou A. C., Baker M. D., McLeod J. D., Goda S. K., Manzotti C. N., Sansom D. M., Tranter H. S., Acharya K. R.. ( 2004;). Identification of a secondary zinc-binding site in staphylococcal enterotoxin C2. Implications for superantigen recognition. . J Biol Chem 279:, 1297–1303. [CrossRef][PubMed]
    [Google Scholar]
  14. Roggiani M., Stoehr J. A., Leonard B. A., Schlievert P. M.. ( 1997;). Analysis of toxicity of streptococcal pyrogenic exotoxin A mutants. . Infect Immun 65:, 2868–2875.[PubMed]
    [Google Scholar]
  15. Schad E. M., Papageorgiou A. C., Svensson L. A., Acharya K. R.. ( 1997;). A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. . J Mol Biol 269:, 270–280. [CrossRef][PubMed]
    [Google Scholar]
  16. Shaw D. M., Connolly N. B., Patel P. M., Kilany S., Hedlund G., Nordle O., Forsberg G., Zweit J., Stern P. L., Hawkins R. E.. ( 2007;). A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. . Br J Cancer 96:, 567–574. [CrossRef][PubMed]
    [Google Scholar]
  17. Sundstedt A., Grundström S., Dohlsten M.. ( 1998;). T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A. . Immunology 95:, 76–82. [CrossRef][PubMed]
    [Google Scholar]
  18. US Pharmacopeia ( 2002;). The United States Pharmacopeia. Rockville, MD:: US Pharmacopeia Convention;.
    [Google Scholar]
  19. Wang X., Zhang H., Xu M., Liu C., Zhang C.. ( 2009;). Biological analysis of the deletion mutants of Staphylococcal enterotoxin C2. . Appl Microbiol Biotechnol 83:, 1077–1084. [CrossRef][PubMed]
    [Google Scholar]
  20. Xu M.-K., Zhang C.-G.. ( 2006;). Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli. . Appl Microbiol Biotechnol 70:, 78–84. [CrossRef][PubMed]
    [Google Scholar]
  21. Xu M., Wang X., Cai Y. M., Zhang H., Yang H., Liu C., Zhang C.. ( 2011;). An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicity. . Cancer Immunol Immunother 60:, 705–713. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.047472-0
Loading
/content/journal/jmm/10.1099/jmm.0.047472-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error